UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 38

Sortiert nach

Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine Approaches

International journal of molecular sciences, 2019-06, Vol.20 (12), p.2976

2019

Volltextzugriff (PDF)

Digital PCR: A Sensitive and Precise Method for KIT D816V Quantification in Mastocytosis

Clinical chemistry (Baltimore, Md.), 2018-03, Vol.64 (3), p.547-555

2018

Volltextzugriff (PDF)

Prognostic factors for intensive care unit admission, intensive care outcome, and post-intensive care survival in patients with de novo acute myeloid leukemia: a single center experience

Haematologica (Roma), 2011-02, Vol.96 (2), p.231-237

2011

Volltextzugriff (PDF)

How I treat patients with advanced systemic mastocytosis

Blood, 2010-12, Vol.116 (26), p.5812-5817

2010

Volltextzugriff (PDF)

Diagnosis and treatment of systemic mastocytosis: state of the art

British journal of haematology, 2003-09, Vol.122 (5), p.695-717

2003

Volltextzugriff (PDF)

New Insights into the Pathogenesis of Mastocytosis: Emerging Concepts in Diagnosis and Therapy

Annual review of pathology, 2023-01, Vol.18, p.361

2023

Volltextzugriff (PDF)

Symptomatic venous thromboembolism in acute leukemia. Incidence, risk factors, and impact on prognosis

Thrombosis research, 2005, Vol.115 (1), p.59-64

2005

Volltextzugriff (PDF)

Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification

Allergy (Copenhagen), 2020-08, Vol.75 (8), p.1923-1934

2020

Volltextzugriff (PDF)

International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study

The Lancet. Haematology, 2019-12, Vol.6 (12), p.e638-e649

2019

Volltextzugriff (PDF)

N‐terminal pro‐brain natriuretic peptide is a prognostic marker for response to intensive chemotherapy, early death, and overall survival in acute myeloid leukemia

American journal of hematology, 2023-02, Vol.98 (2), p.290-299

2023

Volltextzugriff (PDF)

CCL2 is a KIT D816V–dependent modulator of the bone marrow microenvironment in systemic mastocytosis

Blood, 2017-01, Vol.129 (3), p.371-382

2017

Volltextzugriff (PDF)

Eosinophilia in systemic mastocytosis: Clinical and molecular correlates and prognostic significance

Journal of allergy and clinical immunology, 2007-07, Vol.120 (1), p.192-199

2007

Volltextzugriff (PDF)

The serum tryptase test: an emerging robust biomarker in clinical hematology

Expert review of hematology, 2014-10, Vol.7 (5), p.683-690

2014

Volltextzugriff (PDF)

Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group

The journal of allergy and clinical immunology in practice (Cambridge, MA), 2022-08, Vol.10 (8), p.1953-1963

2022

Volltextzugriff (PDF)

Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study

The Lancet. Haematology, 2021-03, Vol.8 (3), p.e194-e204

2021

Volltextzugriff (PDF)

Karyotype plus NPM1 mutation status defines a group of elderly patients with AML (≥60 years) who benefit from intensive post‐induction consolidation therapy

American journal of hematology, 2016-12, Vol.91 (12), p.1239-1245

2016

Volltextzugriff (PDF)

First Experience With a New Miniaturized Pump-Driven Venovenous Extracorporeal CO2 Removal System (iLA Activve): A Retrospective Data Analysis

ASAIO journal (1992), 2014-05, Vol.60 (3), p.342-347

2014

Volltextzugriff (PDF)

Diagnosis, progression patterns and prognostication in mastocytosis

Expert Review of Hematology, 2012-06, Vol.5 (3), p.261-274

2012

Volltextzugriff (PDF)

The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives

The journal of allergy and clinical immunology in practice (Cambridge, MA), 2019-01, Vol.7 (1), p.81-87

2019

Volltextzugriff (PDF)

Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥60 years

American journal of hematology, 2017-10, Vol.92 (10), p.E567-E574

2017

Volltextzugriff (PDF)

Proposed score for survival of patients with myelodysplastic syndromes

European journal of clinical investigation, 2013-11, Vol.43 (11), p.1120-1128

2013

Volltextzugriff (PDF)

Expression and prognostic significance of different mRNA 5′-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration

Genes chromosomes & cancer, 2008-04, Vol.47 (4), p.288-298

2008

Volltextzugriff (PDF)

1 – 25 von 38

Suche als RSS-Feed

Aktive Filter

ThemaOncology

ThemaPrognosis

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(36)
Mit Volltextzugriff
(33)

Publikationsform

Artikel
(37)
Berichte
(1)

Sprache

Englisch
(38)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine Approaches

Digital PCR: A Sensitive and Precise Method for KIT D816V Quantification in Mastocytosis

Prognostic factors for intensive care unit admission, intensive care outcome, and post-intensive care survival in patients with de novo acute myeloid leukemia: a single center experience

Correlation of RAS-Pathway Mutations and Spontaneous Myeloid Colony Growth with Progression and Transformation in Chronic Myelomonocytic Leukemia-A Retrospective Analysis in 337 Patients

How I treat patients with advanced systemic mastocytosis

Diagnosis and treatment of systemic mastocytosis: state of the art

Revised International Prognostic Scoring System for Myelodysplastic Syndromes

New Insights into the Pathogenesis of Mastocytosis: Emerging Concepts in Diagnosis and Therapy

Symptomatic venous thromboembolism in acute leukemia. Incidence, risk factors, and impact on prognosis

Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification

Tumor necrosis factor α promotes clonal dominance of KIT D816V+ cells in mastocytosis: role of survivin and impact on prognosis

International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study

N‐terminal pro‐brain natriuretic peptide is a prognostic marker for response to intensive chemotherapy, early death, and overall survival in acute myeloid leukemia

CCL2 is a KIT D816V–dependent modulator of the bone marrow microenvironment in systemic mastocytosis

Eosinophilia in systemic mastocytosis: Clinical and molecular correlates and prognostic significance

The serum tryptase test: an emerging robust biomarker in clinical hematology

Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group

Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study

Karyotype plus NPM1 mutation status defines a group of elderly patients with AML (≥60 years) who benefit from intensive post‐induction consolidation therapy

First Experience With a New Miniaturized Pump-Driven Venovenous Extracorporeal CO2 Removal System (iLA Activve): A Retrospective Data Analysis

Diagnosis, progression patterns and prognostication in mastocytosis

The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives

Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥60 years

Proposed score for survival of patients with myelodysplastic syndromes

Expression and prognostic significance of different mRNA 5′-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration

Aktive Filter

Suchergebnisse filtern